Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cho

Showing results (261-270 of 299) with videos related to

Pageof 30
Sort By:
Molecular Pharmacology|October 25, 2011
Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system functionMeredith J Noetzel, Jerri M Rook, Paige N Vinson, et al.
ACS Chemical Neuroscience|August 8, 2018
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M<sub>1</sub> Positive Allosteric ModulatorsJulie L Engers, Aaron M Bender, Jacob J Kalbfleisch, et al.
ACS Chemical Neuroscience|September 13, 2016
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M<sub>1</sub> PAM VU6004256Michael D Grannan, Catharine A Mielnik, Sean P Moran, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2012
Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptorBruce J Melancon, Rocco D Gogliotti, James C Tarr, et al.
ACS Chemical Neuroscience|June 23, 2026
Discovery of VU6066098: A Selective and CNS-Penetrant mGlu<sub>2</sub> NAM with Robust Antidepressant-, Antipsychotic-, and Procognitive-like Activity in RodentsJeremy S Coleman, Rory A Capstick, Sichen Chang, et al.
ACS Chemical Neuroscience|November 23, 2012
Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169James C Tarr, Mark L Turlington, Paul R Reid, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Pageof 30

Showing results (261-270 of 299) with videos related to

Sort By:
Pageof 30
Molecular Pharmacology|October 25, 2011
Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system functionMeredith J Noetzel, Jerri M Rook, Paige N Vinson, et al.
ACS Chemical Neuroscience|August 8, 2018
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M<sub>1</sub> Positive Allosteric ModulatorsJulie L Engers, Aaron M Bender, Jacob J Kalbfleisch, et al.
ACS Chemical Neuroscience|September 13, 2016
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M<sub>1</sub> PAM VU6004256Michael D Grannan, Catharine A Mielnik, Sean P Moran, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2021
Discovery of structurally distinct tricyclic M<sub>4</sub> positive allosteric modulator (PAM) chemotypes - Part 2Madeline F Long, Rory A Capstick, Paul K Spearing, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2012
Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptorBruce J Melancon, Rocco D Gogliotti, James C Tarr, et al.
ACS Chemical Neuroscience|June 23, 2026
Discovery of VU6066098: A Selective and CNS-Penetrant mGlu<sub>2</sub> NAM with Robust Antidepressant-, Antipsychotic-, and Procognitive-like Activity in RodentsJeremy S Coleman, Rory A Capstick, Sichen Chang, et al.
ACS Chemical Neuroscience|November 23, 2012
Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169James C Tarr, Mark L Turlington, Paul R Reid, et al.
ACS Chemical Neuroscience|September 24, 2024
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM)Julie L Engers, Logan A Baker, Sichen Chang, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2017
Challenges in the development of an M<sub>4</sub> PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amidesJames C Tarr, Michael R Wood, Meredith J Noetzel, et al.
Pageof 30